EP0000896A2 - Propenyl-amine, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten - Google Patents
Propenyl-amine, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten Download PDFInfo
- Publication number
- EP0000896A2 EP0000896A2 EP78100611A EP78100611A EP0000896A2 EP 0000896 A2 EP0000896 A2 EP 0000896A2 EP 78100611 A EP78100611 A EP 78100611A EP 78100611 A EP78100611 A EP 78100611A EP 0000896 A2 EP0000896 A2 EP 0000896A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- radical
- hydrogen
- compound
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
Definitions
- This invention relates to propenyl-amines, processes for their production and pharmaceutical compositions containing them.
- the present invention provides a compound of formula I,
- Any lower alkyl or lower alkoxy radical has preferably 1 to 4 carbon atoms, especially 2 or 1 carbon atoms.
- Any alkyl(C 1-12 ) moiety is preferably alkyl(C2-8); phenyl- alkyl or phenylalkoxy has preferably 7 carbon atoms.
- Any alkenyl or alkynyl radical has preferably 3 to 6 carbon atoms, especially 3 or 4 carbon atoms.
- the multiple bond is in other than the a, ß position and is conveniently in the remote terminal position.
- An example of an alkenyl group is allyl.
- an alkynyl group is propinyl
- Cycloalkylalkyl has preferably an alkyl moiety of 1 to 4 carbon atoms, especially 2 or 1 carbon atoms, and a cycloalkyl moiety preferably of 3 to 6 carbon atoms.
- R 4 is cycloalkylalkyl this is especially cyclopentyl alkyl or cyclohexylalkyl.
- R 10 is cycloalkylalkyl this is especially cyclopropylalkyl or cyclobutylalkyl.
- R 7 and R 8 are identical and are both hydrogen.
- R 9 is hydrogen or halogen.
- IIb and IIc the bond to the carbon atom to which R 2 and R 3 are attached is conveniently attached meta to X and para to the ring nitrogen, respectively.
- X is conveniently sulphur, imino or lower alkylamino.
- R 1 is preferably a radical of formula IIb, IIc or IId or especially IIa.
- R 2 is preferably hydrogen.
- R 3 is preferably hydrogen and R 4 is conveniently alkyl.
- R 5 is conveniently hydrogen.
- R 6 when it is a heterocycleconveniently contains one oxygen or sulphur atom or one or two nitrogen atoms.
- the bond linking R 6 to the vinylene moiety is attached to a ring carbon atom adjacent to a ring heteroatom.
- the ring is unsubstituted or substituted by lower alkyl.
- R 10 is conveniently phenylalkoxy. IIa is conveniently optionally substituted 2 or 4-pyridyl.
- IIIc is preferably a cycloalk-1-en-1-yl radical.
- R 11 to R 13 are hydrogen.
- q is conveniently 0 or 1.
- R 14 is conveniently alkoxy (C 1-8 ) carbonyl, phenyl or alkyl or phenalkyl.
- R 17 is conveniently halogen and R 18 is conveniently hydrogen.
- R 6 is conveniently IIIc.
- u is conveniently 3, 4 or 5, more conveniently 4.
- m, n, p, q, s, t and v are conveniently chosen to produce a five or six-membered ring.
- the double bond between R 6 and the nitrogen atom preferably has the trans configuration.
- Halogen is conveniently fluorine, or preferably bromine or chlorine.
- R 1 is IIb or IIe and R 6 is IIIa it is to be appreciated that the two radicals R 9 may be the same or different.
- the present invention also provides a process for the production of a compound of formula I, which comprises
- Process a) may be effected in conventional manner for the production of tertiary amines by condensation from analogous starting materials.
- the process may be effected in an inert solvent such as a lower alkanol, e.g. ethanol, optionally in aqueous admixture, an aromatic hydrocarbon solvent, e.g. benzene or toluene, a cyclic ether, e.g. dioxane or a carboxylic acid dialkylamide solvent, e.g: dimethylformamide.
- the reaction temperature is conveniently from room temperature to the boiling temperature of the reaction mixture, preferably room temperature.
- the reaction is conveniently effected in the presence of an acid binding agent, such as an alkali metal carbonate, e.g.
- the leaving group A is conveniently iodine or preferably chlorine or bromine, or an organic sulphonyloxy group having 1 to 10 carbon atoms, e.g. alkylsulphonyloxy, preferably having 1 to 4 carbon atoms such as mesyloxy, or alkylphenylsulphonyloxy preferably having 7 to 10 carbon atoms such as tosyloxy.
- Process b) may be effected in conventional manner for catalytic hydrogenation in order to produce a compound of formula Ia wherein the double bond adjacent to has the cis configuration.
- the process may be effected in conventional manner for a complex metal hydride reduction in order to produce a-compound of formula Ia wherein the double bond has the trans configuration.
- the catalytic hydrogenation may be effected in a solvent, e.g. methanol, ethanol, methylene chloride, pyridine or ethyl acetate.
- the catalyst is preferably palladium on a carrier material such as BaSO 4 or CaC0 3 .
- the catalyst may be pretreated, e.g. with a lead salt, so as to be partially poisoned (e.g. a Lindlar catalyst).
- the hydrogenation may be effected at room temperature and at normal pressure.
- the metal hydride reduction may be effected in conventional manner for a lithium aluminium hydride or a diisobutylaluminium hydride reduction.
- the reduction is conveniently effected in an inert solvent such as toluene or benzene.
- the reaction is conveniently effected at room temperature.
- Process c) may be effected in conventional manner for a photochemical isomerisation of a cis alkene.
- the reaction may be effected in a solvent such as benzene, petroleum ether, ethanol, or preferably cyclohexane.
- the solution is conveniently irradiated with light from a mercury high or low pressure lamp.
- the reaction is conveniently effected at room temperature.
- an appropriate sensitizer such as eosine or a catalyst such as diphenyldisulphide may be present.
- Process d) may be effected in manner conventional for the "alkylation" of secondary amines (the term “alkylation” being used here to denote introduction of any of the hydrocarbyl groups RQ I ), for example by direct “alkylation” with an “alkylating” agent, for example a. halide or sulphate, or by reductive alkylation, in particular by reaction with an appropriate aldehyde and subsequent or simultaneous reduction.
- Reductive "alkylation” is suitably effected in an inert organic solvent, such as a lower alkanol, e.g. methanol, and at an elevated temperature, in particular at the boiling temperature of the reaction medium.
- the subsequent reduction may be effected with, for example, a complex metal hydride reducing agent, e.g. NaBH 4 or LiAlH 4 .
- a complex metal hydride reducing agent e.g. NaBH 4 or LiAlH 4 .
- the reduction may also be effected simultaneously to the alkylation, for example by use of formic acid which may serve both as reducing agent and as a reaction medium.
- side reactions may occur, e.g. reduction of halogen to hydrogen, reduction of a nitro group to an amino group, reduction of an alkenyl moiety to an alkyl moiety and/or reduction of a keto moiety to a carbinol moiety in processes b) or process d) when reductive alkylation is used, or simultaneous cis/trans isomerisation of any double bond present in R 4 or R 6 when process c) is used.
- the reaction conditions should be chosen to avoid such side reactions, and the desired final product isolated using conventional purification techniques, e.g. thin layer chromatography.
- Free base forms of the compounds of formula I may be converted into salt forms and vice versa.
- Suitable acids for acid addition salt formation include hydrochloric acid, fumaric acid and naphthalene-l,5-disulphonic acid.
- non-cyclic amines of formula IV may be made by condensing a compound of. formula VIII, or the corresponding iodide or chloride, with a compound of formula
- the compounds of formula VI are new and may be made by reacting an appropriate amine of formula IV with compounds of formulae R 5 -CHO and HC ⁇ CR under Mannich reaction conditions.
- the title compound may also be made in analogous manner to Examples 3, 4 and 5.
- the title compound may also be made in analogous manner to Examples 1 and 5.
- the title compound may also be prepared by following Examplesl, 4 and 5.
- the title compound may also be prepared by following Examples 1, 3 and 5.
- the title compound may also be prepared in analogous manner to Examples 1, 3 and 4.
- NMR data on the above-mentioned compounds of formula I, obtained as oils, are given in the following table.
- the compounds of formula I exhibit chemotherapeutic activity.
- they exhibit antimycotic activity, as indicated in vitro with tests against various families and types of mycetes, including Trichophton quinkeanum, Aspergillus fumigatus, Microsporum canis, Sporotrychium schenkii and Candida albicans, at concentrations of, for example 0.1 to 100 pg/ml, and in vivo in the experimental skin mycosis model in guinea pigs. In the latter model, guinea pigs are infected by cutaneous application of Trichophyton quinkeanum.
- test substance is administered daily for 7 days beginning 24 hours after the infection by local application by rubbing the test substance (taken up in polyethylene glycol) on the skin surface, or perorally, the test substance being administered as a suspension.
- the activity is shown on local application at concentrations of from example 0.1 to 2%, in particular 0.1 to 0.6%.
- the oral activity is shown at dosages of, for example, 50 to 100 mg/kg.
- the compounds are therefore indicated for use as anti-mycotic agents.
- An indicated daily dose is from 500 to 2000 mg. If desired, this may be administered in divided doses 2 to 4 times a day in unit dosage form containing from about 125 mg to about 1000 mg or in sustained release form.
- the compounds may be used in free base form or in the form of chemotherapeutically acceptable acid addition salts. Such salt forms exhibit the same order of activity as the free base forms.
- the compounds may be admixed with conventional chemotherapeutically acceptable diluents and carriers, and, optionally, other excipients and administered in such forms as tablets or capsules.
- the compounds may alternatively be administered topically in such conventional forms as ointments or creams.
- concentration of the active substance in such topical application forms will of course vary depending on the compound employed, the treatment desired and the nature of the form etc. In general, however, satisfactory results are obtained at concentrations of from 0.05 to 3 , in particular 0.1 to 1 wt %.
- a compound with particularly interesting activity is the compound of Example 4.
- One group of compounds has a formula Ig,
- Another group of compounds comprises those of formula Ih,
- a further group of formula I compounds comprises compounds of formula Ii, wherein R III 1 is a radical of formula IIa, IIb wherein X is oxygen or sulphur, IIc, IId wherein s is 4, IIe wherein t is 3, or a radical of formula R 2 , R 3 , R 4 , R 5 and R 9 are as defined above, with the proviso that R 3 and R 4 are other than -(CH 2 ) 11 -, is as defined above for R 6 with respect to formula I, with the following provisos
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1020377A CH632251A5 (en) | 1977-08-19 | 1977-08-19 | Process for preparing novel 2-naphthyl-substituted, cyclic, N-allylamine derivatives |
CH1020277 | 1977-08-19 | ||
CH10203/77 | 1977-08-19 | ||
CH10202/77 | 1977-08-19 | ||
CH12910/77 | 1977-10-24 | ||
CH1291077 | 1977-10-24 | ||
CH12909/77 | 1977-10-24 | ||
CH1290977 | 1977-10-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0000896A2 true EP0000896A2 (de) | 1979-03-07 |
EP0000896A3 EP0000896A3 (en) | 1979-05-30 |
EP0000896B1 EP0000896B1 (de) | 1982-10-13 |
Family
ID=27429271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100611A Expired EP0000896B1 (de) | 1977-08-19 | 1978-08-07 | Propenyl-amine, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten |
Country Status (14)
Country | Link |
---|---|
US (1) | US4680291A (de) |
EP (1) | EP0000896B1 (de) |
JP (1) | JPS5441855A (de) |
CA (1) | CA1111852A (de) |
DE (1) | DE2862103D1 (de) |
DK (1) | DK152114C (de) |
ES (1) | ES472641A1 (de) |
FI (1) | FI65774C (de) |
IE (1) | IE47314B1 (de) |
IL (1) | IL55382A (de) |
IT (1) | IT1098253B (de) |
MY (1) | MY8500040A (de) |
NZ (1) | NZ188170A (de) |
PT (1) | PT68448A (de) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2462426A1 (fr) * | 1979-06-08 | 1981-02-13 | Sandoz Sa | Nouveau derive de la 2-(1-naphtyl)piperidine, sa preparation et son application comme medicament |
EP0024587A1 (de) * | 1979-08-22 | 1981-03-11 | Sandoz Ag | Propenylamine, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwendung als Arzneimittel |
EP0041293A1 (de) * | 1980-05-30 | 1981-12-09 | Akzo N.V. | Biologisch aktive trizyklische Amine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
FR2500823A1 (fr) * | 1981-03-02 | 1982-09-03 | Abbott Lab | 1-aminoalkyl-1, 2, 3, 4-tetrahydroanphtalenes mono- ou disubstitues utiles notamment comme adrenergiques et medicaments les contenant |
FR2520741A1 (fr) * | 1982-02-03 | 1983-08-05 | Sandoz Sa | Nouveaux derives du benzothiophene, leur preparation et leur utilisation comme medicaments |
EP0164697A2 (de) * | 1984-06-09 | 1985-12-18 | Kaken Pharmaceutical Co., Ltd. | Aminderivate, Verfahren zu ihrer Herstellung und diese enthaltende Fungizide |
EP0254677A1 (de) * | 1986-07-08 | 1988-01-27 | Sandoz Ag | Antimykotische 6-Phenyl-2-hexen-4-ynamine |
US4822822A (en) * | 1985-11-01 | 1989-04-18 | Mitsui Toatsu Chemicals, Inc. | Benzylamine derivatives, and use thereof |
US5334628A (en) * | 1984-06-09 | 1994-08-02 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives, processes for preparing the same and fungicides containing the same |
US5935998A (en) * | 1995-07-06 | 1999-08-10 | Novartis Ag | Use of all allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases |
AU723758B2 (en) * | 1996-08-01 | 2000-09-07 | Dow Agrosciences Llc | 4-substituted quinoline derivatives having fungicidal activity |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084476A (en) * | 1986-07-15 | 1992-01-28 | Hoffmann-La Roche Inc. | Tetrahydronaphthalene and indane derivatives |
US5234946A (en) * | 1987-11-27 | 1993-08-10 | Banyu Pharmaceutical Co., Ltd. | Substituted alkylamine derivatives |
JPH03105465U (de) * | 1990-02-16 | 1991-10-31 | ||
US6117884A (en) * | 1997-07-31 | 2000-09-12 | Daeuble; John | 4-substituted quinoline derivatives having fungicidal activity |
JP4509327B2 (ja) * | 2000-08-03 | 2010-07-21 | ダイセル化学工業株式会社 | N,n−ジ置換−4−アミノクロトン酸エステルの製造方法 |
US20050197512A1 (en) * | 2003-08-29 | 2005-09-08 | Ulrich Beutler | Purification process |
GB0320312D0 (en) | 2003-08-29 | 2003-10-01 | Novartis Ag | Purification process |
WO2006003492A2 (en) * | 2004-07-02 | 2006-01-12 | Warner-Lambert Company Llc | Compositions and methods for treating pathological infections |
JP2009502258A (ja) * | 2005-07-21 | 2009-01-29 | ノミール・メディカル・テクノロジーズ・インコーポレーテッド | 標的部位の生物学的汚染物質のレベルを下げる方法 |
US20090082469A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched terbinafine |
WO2017132912A1 (zh) * | 2016-02-03 | 2017-08-10 | 华东理工大学 | 苯并脂肪环取代烷基胺类化合物及其用途 |
CN108084125B (zh) * | 2016-11-23 | 2020-08-18 | 华东理工大学 | 苯并杂环烷基胺类化合物及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2137276A1 (de) * | 1971-07-26 | 1973-02-08 | Basf Ag | N-substituierte 1-aminomethylindane |
DE2303245A1 (de) * | 1972-01-28 | 1973-08-02 | Richardson Merrell Inc | Olefinisch substituierte piperidinderivate und verfahren zu deren herstellung |
GB1404021A (en) * | 1971-11-19 | 1975-08-28 | Basf Ag | 1-aminomethylace-naphthenes and their production |
DE2716943A1 (de) * | 1976-04-28 | 1977-11-17 | Sandoz Ag | Organische verbindungen, ihre verwendung und herstellung |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE609151C (de) * | 1930-02-01 | 1935-02-08 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von Aminoalkoholen mit sekundaerer oder tertiaerer Aminogruppe |
US2601275A (en) * | 1949-10-29 | 1952-06-24 | Givaudan Corp | Aromatic chlorethylamines and their salts |
DK106378C (da) * | 1962-10-19 | 1967-01-30 | Koninklijke Pharma Fab Nv | Fremgangsmåde til fremstilling af N-substituerede 1-phenyl-2-aminoalkaner eller syreadditionssalte heraf. |
GB1041987A (en) * | 1964-09-03 | 1966-09-07 | Beecham Group Ltd | Acetylenic compounds |
GB1134715A (en) * | 1966-02-24 | 1968-11-27 | Geistlich Soehne Ag | Bisphenylalkenylamine derivatives |
US3784642A (en) * | 1967-11-03 | 1974-01-08 | E Jenny | 1-amine-cyclobutene |
BE791133A (fr) * | 1971-11-10 | 1973-05-09 | Calgon Corp | Nouveaux monomeres cationiques et leurs procedes de fabrication |
JPS4930346A (de) * | 1972-07-18 | 1974-03-18 | ||
US4139560A (en) * | 1974-02-22 | 1979-02-13 | Ciba Geigy Corporation | Nonylamines |
HU169507B (de) * | 1974-09-25 | 1976-12-28 |
-
1978
- 1978-08-07 DE DE7878100611T patent/DE2862103D1/de not_active Expired
- 1978-08-07 EP EP78100611A patent/EP0000896B1/de not_active Expired
- 1978-08-10 FI FI782446A patent/FI65774C/fi not_active IP Right Cessation
- 1978-08-10 DK DK354678A patent/DK152114C/da not_active IP Right Cessation
- 1978-08-17 CA CA309,579A patent/CA1111852A/en not_active Expired
- 1978-08-17 IL IL55382A patent/IL55382A/xx active IP Right Grant
- 1978-08-17 NZ NZ188170A patent/NZ188170A/xx unknown
- 1978-08-17 IE IE1670/78A patent/IE47314B1/en not_active IP Right Cessation
- 1978-08-17 ES ES472641A patent/ES472641A1/es not_active Expired
- 1978-08-18 US US06/934,772 patent/US4680291A/en not_active Expired - Lifetime
- 1978-08-18 PT PT68448A patent/PT68448A/pt unknown
- 1978-08-18 IT IT26835/78A patent/IT1098253B/it active
- 1978-08-19 JP JP10137578A patent/JPS5441855A/ja active Granted
-
1985
- 1985-12-30 MY MY40/85A patent/MY8500040A/xx unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2137276A1 (de) * | 1971-07-26 | 1973-02-08 | Basf Ag | N-substituierte 1-aminomethylindane |
GB1404021A (en) * | 1971-11-19 | 1975-08-28 | Basf Ag | 1-aminomethylace-naphthenes and their production |
DE2303245A1 (de) * | 1972-01-28 | 1973-08-02 | Richardson Merrell Inc | Olefinisch substituierte piperidinderivate und verfahren zu deren herstellung |
DE2716943A1 (de) * | 1976-04-28 | 1977-11-17 | Sandoz Ag | Organische verbindungen, ihre verwendung und herstellung |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2462426A1 (fr) * | 1979-06-08 | 1981-02-13 | Sandoz Sa | Nouveau derive de la 2-(1-naphtyl)piperidine, sa preparation et son application comme medicament |
EP0024587A1 (de) * | 1979-08-22 | 1981-03-11 | Sandoz Ag | Propenylamine, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwendung als Arzneimittel |
US4755534A (en) * | 1979-08-22 | 1988-07-05 | Sandoz Ltd. | Propenylamines, pharmaceutical compositions containing them and their use as pharmaceuticals |
EP0041293A1 (de) * | 1980-05-30 | 1981-12-09 | Akzo N.V. | Biologisch aktive trizyklische Amine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
WO1981003490A1 (en) * | 1980-05-30 | 1981-12-10 | Akzo Nv | Biologically-active tricyclic amines,methods for their preparation and pharmaceutical compositions containing same |
FR2500823A1 (fr) * | 1981-03-02 | 1982-09-03 | Abbott Lab | 1-aminoalkyl-1, 2, 3, 4-tetrahydroanphtalenes mono- ou disubstitues utiles notamment comme adrenergiques et medicaments les contenant |
US4737516A (en) * | 1982-02-03 | 1988-04-12 | Sandoz Ltd. | Benzothienylallylamines processes for their production and their use as pharmaceuticals |
FR2520741A1 (fr) * | 1982-02-03 | 1983-08-05 | Sandoz Sa | Nouveaux derives du benzothiophene, leur preparation et leur utilisation comme medicaments |
US5021458A (en) * | 1984-06-09 | 1991-06-04 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives and fungicides containing the same |
EP0164697A3 (en) * | 1984-06-09 | 1987-04-29 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives, processes for preparing the same and fungicides containing the same |
EP0164697A2 (de) * | 1984-06-09 | 1985-12-18 | Kaken Pharmaceutical Co., Ltd. | Aminderivate, Verfahren zu ihrer Herstellung und diese enthaltende Fungizide |
US5106866A (en) * | 1984-06-09 | 1992-04-21 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives, processes for preparing the same and fungicides containing the same |
US5200423A (en) * | 1984-06-09 | 1993-04-06 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives, processes for preparing the same and fungicides containing the same |
US5334628A (en) * | 1984-06-09 | 1994-08-02 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives, processes for preparing the same and fungicides containing the same |
USRE34770E (en) * | 1984-06-09 | 1994-11-01 | Kaken Pharmaceutical Co., Ltd. | Amine derivatives, processes for preparing the same and fungicides containing the same |
US4822822A (en) * | 1985-11-01 | 1989-04-18 | Mitsui Toatsu Chemicals, Inc. | Benzylamine derivatives, and use thereof |
EP0254677A1 (de) * | 1986-07-08 | 1988-01-27 | Sandoz Ag | Antimykotische 6-Phenyl-2-hexen-4-ynamine |
US5935998A (en) * | 1995-07-06 | 1999-08-10 | Novartis Ag | Use of all allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection or associated diseases |
AU723758B2 (en) * | 1996-08-01 | 2000-09-07 | Dow Agrosciences Llc | 4-substituted quinoline derivatives having fungicidal activity |
Also Published As
Publication number | Publication date |
---|---|
MY8500040A (en) | 1985-12-31 |
IE781670L (en) | 1979-02-19 |
NZ188170A (en) | 1981-05-01 |
DK152114B (da) | 1988-02-01 |
CA1111852A (en) | 1981-11-03 |
IL55382A (en) | 1981-12-31 |
IL55382A0 (en) | 1978-10-31 |
EP0000896A3 (en) | 1979-05-30 |
US4680291A (en) | 1987-07-14 |
FI65774B (fi) | 1984-03-30 |
FI65774C (fi) | 1984-07-10 |
DK354678A (da) | 1979-02-20 |
JPS5441855A (en) | 1979-04-03 |
EP0000896B1 (de) | 1982-10-13 |
IE47314B1 (en) | 1984-02-22 |
IT1098253B (it) | 1985-09-07 |
PT68448A (fr) | 1978-09-01 |
DE2862103D1 (en) | 1982-11-18 |
ES472641A1 (es) | 1979-10-16 |
JPS6317050B2 (de) | 1988-04-12 |
IT7826835A0 (it) | 1978-08-18 |
DK152114C (da) | 1988-06-20 |
FI782446A (fi) | 1979-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0000896B1 (de) | Propenyl-amine, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
EP0024587B1 (de) | Propenylamine, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwendung als Arzneimittel | |
KR100446893B1 (ko) | Cns 장해 치료용 모노아민 재흡수 억제제 | |
AU778596B2 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives | |
EP0288188A1 (de) | 1-Phenyl-3-naphthalenyloxy-propanamine | |
CA2004575A1 (en) | 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics | |
CA2005173A1 (en) | Serotonin and norepinephrine inhibitors | |
FI65058B (fi) | Foerfarande foer framstaellning av nya kemoterapeutiskt anvaendbara kinnamyl-(1-naftylmetyl)aminoderivat | |
US3660487A (en) | N-(alkyl) alkanesulfonamido phenethanolamines | |
IE46278B1 (en) | Piperazine derivatives | |
CA2541066C (fr) | Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2758328A1 (fr) | Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments | |
HU209481B (en) | Process for the production of substituted 2-amino-1,2,3,4-tetrahydro-naphthalene and 3-aminochromane derivatives | |
US5132459A (en) | Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals | |
EP0318233A2 (de) | Serotonin- und Norepinephrin-Aufnahme-Inhibitoren | |
US4272533A (en) | N-Phenylindoline derivatives, and pharmaceutical compositions containing them | |
EP0246077B1 (de) | Heteropolyzyklische aromatische Verbindungen | |
US3674807A (en) | 1-p-(omega-aminoalkyl)phenyl-cyclohexanes,cyclohexenes and cyclohexanols | |
US2992231A (en) | Pyrrolidyl derivatives of 3-arylindenes and 3-arylindanes | |
NZ230628A (en) | Ring-substituted alkylene amine derivatives, preparatory intermediates and pharmaceutical compositions | |
EP0318234A2 (de) | Selektive Sertonin-Aufnahme-Inhibitoren | |
US2584131A (en) | Pyrrolidyl thiolesters | |
JPH0149690B2 (de) | ||
JPH0454668B2 (de) | ||
US4018897A (en) | Antiarrhythmic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE FR GB LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2862103 Country of ref document: DE Date of ref document: 19821118 |
|
EPTA | Lu: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 78100611.9 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Free format text: SANDOZ AG TRANSFER- NOVARTIS AG |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19970602 Year of fee payment: 20 Ref country code: FR Payment date: 19970602 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19970604 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19970605 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19970609 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19970630 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19970707 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19970813 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
BE20 | Be: patent expired |
Free format text: 980807 *SANDOZ A.G. |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980806 Ref country code: CH Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980806 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980807 Ref country code: LU Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19980807 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980808 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Effective date: 19980806 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 19980807 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78100611.9 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |